UroGen Pharma
URGN
About: UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Employees: 253
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
152% more call options, than puts
Call options by funds: $35.4M | Put options by funds: $14.1M
33% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 30
18% more capital invested
Capital invested by funds: $460M [Q1] → $545M (+$84.9M) [Q2]
7% more funds holding
Funds holding: 139 [Q1] → 149 (+10) [Q2]
10% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 41
3.96% less ownership
Funds ownership: 90.27% [Q1] → 86.31% (-3.96%) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 6 [Q1] → 4 (-2) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
Piper Sandler
Kelsey Goodwin
|
$36
|
Overweight
Initiated
|
19 Aug 2025 |
|
HC Wainwright & Co.
Raghuram Selvaraju
|
$40
|
Buy
Maintained
|
11 Aug 2025 |
|
D. Boral Capital
Jason Kolbert
|
$25
|
Buy
Maintained
|
7 Aug 2025 |
Financial journalist opinion
Based on 3 articles about URGN published over the past 30 days
